These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35563039)

  • 1. Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform.
    Lee P; Yim R; Fung SH; Miu KK; Wang Z; Wu KC; Au L; Leung GM; Lee VH; Gill H
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies.
    Zhang X; Lv D; Zhang Y; Liu Q; Li Z
    Oncotarget; 2016 Sep; 7(36):58586-58594. PubMed ID: 27474172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
    Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
    Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.
    Chen J; Kao YR; Sun D; Todorova TI; Reynolds D; Narayanagari SR; Montagna C; Will B; Verma A; Steidl U
    Nat Med; 2019 Jan; 25(1):103-110. PubMed ID: 30510255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
    Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
    Pegliasco J; Hirsch P; Marzac C; Isnard F; Meniane JC; Deswarte C; Pellet P; Lemaitre C; Leroy G; Rabadan Moraes G; Guermouche H; Schmaltz-Panneau B; Pasquier F; Colas C; Benusiglio PR; Bera O; Bourhis JH; Brissot E; Caron O; Chraibi S; Cony-Makhoul P; Delaunay-Darivon C; Lapusan S; de Fontbrune FS; Fuseau P; Najman A; Vainchenker W; Delhommeau F; Micol JB; Plo I; Bellanné-Chantelot C
    Leukemia; 2022 Jan; 36(1):126-137. PubMed ID: 34172895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
    Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
    Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
    Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
    Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
    Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.